Cingulate CINGW
NASDAQ CINGW
$0.01 +0.00 (+4.29%)
As of: Sep 9, 2026 · 11:16 AM EDT

Cingulate (CINGW) Net Equity Issued and Repurchased (2023 - 2026)

Cingulate's (CINGW) quarterly Net Equity Issued and Repurchased came in at $5.1 million in Q2 2026, little changed on a YoY basis from $5.1 million in Q2 2025, and up 95.46% quarter-over-quarter from $2.6 million in Q4 2025.

Analysis

Cingulate (CINGW) Net Equity Issued and Repurchased (2023 - 2026) Analysis & Trends

Cingulate (CINGW) has reported Net Equity Issued and Repurchased for 4 consecutive years, with $5.1 million the latest figure, recorded in Q2 2026.

  • For the quarter ending Q2 2026, Net Equity Issued and Repurchased changed 0.0% year-over-year to $5.1 million; the trailing twelve-month figure through Jun 2026 stood at $13.9 million (down 4.79% YoY), and the FY2025 full-year result was $10.2 million, down 60.76% from the prior year.
  • Net Equity Issued and Repurchased rose to $5.1 million in Q2 2026 per CINGW's latest filing, from $2.6 million in the prior quarter.
  • Across five years, Net Equity Issued and Repurchased topped out at $9.9 million in Q1 2024 and bottomed at $254260.0 in Q2 2023.
  • Historically, Net Equity Issued and Repurchased has averaged $3.2 million across 4 years, with a median of $2.3 million in 2025.
  • The widest YoY moves for Net Equity Issued and Repurchased: up 1328.04% in 2025, down 81.13% in 2025.
  • Over 4 years, Net Equity Issued and Repurchased stood at $819538.0 in 2023, then soared by 81.76% to $1.5 million in 2024, then soared by 73.76% to $2.6 million in 2025, then soared by 95.46% to $5.1 million in 2026.
  • According to Business Quant data, Net Equity Issued and Repurchased over the past three periods registered $5.1 million, $2.6 million, and $1.1 million for Q2 2026, Q4 2025, and Q3 2025 respectively.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Equity Issued and Repurchased (Qtr)
1 Johnson & Johnson 644.32 Bn 623.56 Bn 17.26 Bn -
2 AbbVie 440.60 Bn 434.04 Bn 12.70 Bn -
3 Merck 365.39 Bn 358.25 Bn 12.21 Bn -
4 Novartis Ag 266.73 Bn 259.04 Bn 11.24 Bn -
5 Pfizer 159.22 Bn 147.52 Bn 10.94 Bn -
6 Sanofi 52.48 Bn 45.10 Bn 10.79 Bn -
7 Revolution Medicines 44.21 Bn 44.21 Bn - 141.90 Mn
8 Incyte 25.34 Bn 20.81 Bn 1.57 Bn -
9 United Therapeutics 21.49 Bn 18.82 Bn 683.80 Mn -
10 Cingulate 100,214.03 100,214.03 - 5.06 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 5.06 Mn
Dec 31, 2025 2.59 Mn
Sep 30, 2025 1.15 Mn
Jun 30, 2025 5.06 Mn
Mar 31, 2025 1.92 Mn
Dec 31, 2024 1.49 Mn
Sep 30, 2024 6.08 Mn
Jun 30, 2024 354,259.00
Mar 31, 2024 9.89 Mn
Dec 31, 2023 819,538.00
Sep 30, 2023 3.30 Mn
Jun 30, 2023 254,260.00